[Skip to Content]
[Skip to Content Landing]
Views 45
Citations 0
Comment & Response
March 19, 2018

Efficiency of Deamidated Gliadin Peptides for Screening Celiac Disease Autoimmunity—Reply

Author Affiliations
  • 1Department of Clinical Sciences, Lund University Clinical Research Center, Skåne University Hospital, Malmo, Sweden
  • 2Digestive Health Institute, Children’s Hospital Colorado, Anschutz Medical Campus, University of Colorado Denver, Aurora
  • 3Department of Microbiology and Cell Science, Institute of Food and Agricultural Sciences, University of Florida, Gainesville
JAMA Pediatr. Published online March 19, 2018. doi:10.1001/jamapediatrics.2018.0041

In Reply We thank the Rahmoune et al for their comments and critical reading of our article.1 However, we respectfully disagree with the authors that analyzing antibodies against deamidated gliadin peptides (DGP) would have changed the outcome for detecting celiac disease in our study population of genetically at-risk children.

It is true that the DGP antibody assay may also detect children younger than 2 years who are IgA–tissue transglutaminase (TTG) negative with very early onset of celiac disease.2 However, most of these previous studies are retrospectively analyzed using clinical material already selected owing to being IgA-TTG or endomysial antibody positive, resulting in a falsely high diagnostic specificity.

First Page Preview View Large
First page PDF preview
First page PDF preview
×